Breast			
2nd line ER/+Her- Advanced Breast cancer	ARV-471 vs Fulvestrant	**Pfizer C4891001**: **Inclusion Criteria**: ER+ Her2- advanced BC, no more then 1 line of CDK4/6 inhibitor therapy in combination w ET therapy, must have at least 6months of ET prior to PD, Measurable disease, ECOG 0-1, *(neodjuvant/adjuvant tx is counted as a line for locoreginal recurrent or metastatic disease if relapse occurs on or w/in 12 months of last dose*) **Exclusion Criteria:** no prior tx with Fulvestrant, ARV-471, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitors, chemotherapy in locally advanced or metastatic setting, CDK 4/6 inhibitor tx in neo/adjuvant setting, brain or CNS mets, planned major surgery w/in 2 weeks, endocrine or CDK4/6 inhibitor therapy w/in 2 weeks of randomization (14 day wash out required)	Phase III UCLA/TRIO UCLA PI: McAndrew PI: RP SC: Maria
Lung			
2nd line NSCLC with known AGAs EGFR ALK mutations previously treated	SGNB6A vs Docetaxel	**Pfizer: Seagen SGNB6A-002 Inclusion Criteria**:patients previously treated with platinum-based chemotherapy and PD-L1 antibody, measurable disease, ECOG 0-1 **Exculsion criteria**: prior tx with docetaxel, life expectancy <3 months, CNS mets	Phase III UCLA/TRIO UCLA PI: Lisberg PI: RP SC: Maria
non-squamous NSCLC EGRF + Stage IIIB/IIIC or Metastatic Stage IV	AK112(SMT112) w pemetrexed & Carboplatin vs placebo w pemetrexed & Carboplatin	**Summit AK112-301**: **Inclusion Criteria:** Patients with non-squamous NSCLC w EGFR mutation who have disease progression following tx w 1st /2nd Gen EGFR-TKI. Measureable disease ECOG 0-1. **Exlcusion Criteria :** No CNS mets., No presence of small cell carcinoma component squamous cell carcinoma. No prior tx with immunotherapy including immune checkpoint inhibitors, agonist. No prior chemotherapies in metastatic NSCLC or EGFR inhibitor therapy, no active autoimmune diseases.	Phase III UCLA/TRIO UCLA PI: Goldman PI: RP SC: Maria

Colorectal			
1st line Colorectal Cancer with KRAS/NRAS Mutation	open-label, Ovansertib w FOLFIRI /FOLFOX w Bevacizumab vs FLOFIRI/FOLFOX w Bevacizumab	**Pfizer Z0101001/CRDF004: Inclusion Criteria:**1st line Colorectal; no prior tx in metastatic setting. Must have KRAS/NRAS mutation status. Archival tissue or fresh biopsy for central KRAS/NRAS testing, (local RAS testing can be performed), ECOG 0 -1 Measurable disease per Recist 1.1 **Exclusion Criteria:** No prior oxaliplatin treatment within 12 months prior to randomization. No BRAF V600 mutation,	Phase II UCLA/TRIO UCLA PI: Hecht PI: RP SC: Maria
Solid Tumors			
Metastatic Solid tumors to which no SOC is available or intolerant to SOC therapy	single agent GIM-531 w Anti-PD1	**Georgimmune GIM531-CT01: Inclusion Criteria:** solid tumors with cytologicaly or histological confirmed locally advanced metastatic solid tumor that have progressed on standard therapy or for which **NO** standard therapy exist; or be **intolerant** of standard of therapy, life expectancy ≥3months, ECOG 0-1, archival tissue available for central testing or fresh tissue core needle biopsy, measurable disease per recist 1.1 **Exclusion Criteria:** brain mets, cardiopulmonary disease, structual cardiac disease, QTcF > 470 on ECG, active autoimmune disease, melanoma with documented BRAF mutation,	Phase I/II CBCC Private PI: RP SC Nicole/Maria
Pretreatment Patients Only	no tx	**OncoFiltration CO2300017**: **Inclusion Criteria:** pre-treatment patients with a solid tumor (i.e. breast, lung, colorectal, prostate cancer diagnosis) Study is currently enrolling for: **newly diagnosed breast cancer patients Stage IA. Subjects willing to provide 40mL of whole blood. Exclusion Criteria: NO** prior treatment or surgery for their disease, patients who have donated bone marrow within the last 3 months, patient who are anemic defined as a hemoglobin >10.0g/dL for men or > 12 g/dL for women, Positive for Infectious disease: HIV, HbsAg/HCV.	Phase I/II CBCC Private PI: RP SC Nicole/Maria